A Phase 3 Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
Status:
Recruiting
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study
in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients
will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared
to placebo.